DXCM DexCom, Inc.

XNAS 83.33 +0.00% After hours
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

DXCM $83.33 ▲ +0.00%
Key stats
$83.33
After hours $83.33 +0.00%
52-Week Range
$56.72 – $92.59
YTD
+25.23%
IV Rank (30D)
25.31
Straddle Price
$6.80
P/C Vol Ratio
1.13
Market Cap
$30.4B
Open
$82.00
Day Range
$81.39 – $83.66
Volume
2,971,220
Prev Close
$81.39
Fair Value
MODEL: NEUTRAL

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.88%
Beta vs SPY1.12
Cost of Equity (CAPM)10.21% (VRP-adj)
WACC10.33%
Volatility Risk Premium-4.3pp (IV − HV30), ERP adj -25bps
Effective Tax Rate21.5%
Rev. Growth (YoY, DCF input)+6.7%
DCF Horizon12 years explicit + fade
Forward Tilt (NTM/TTM)×1.07 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$1.1B
Return on Equity (TTM)39.1%
Book / Price8.1%
Gross Margin (TTM)63.4%
FCF Margin (TTM)21.5%
Debt / Equity0.49
Quality Score5/6 — high quality (12y DCF)
Market-Implied Growth+15.2% (reverse-DCF on current price)
SMA 50$84.43 (Market Anchor value)
SMA 20 / Bollinger Mid$81.75
Bollinger Width / SMA2015.0% (drives anchor stability)
Net Debt$0.3B
Market Cap$31B
Peers used for multiples: ABT, GEHC, ISRG, LLY, NTRA, PODD, RMD, VRTX
60-Day Conviction
5%
20-Day Fair Value
≈ by Dec 14, 2026
$83.20
α -0.0% rank 33%
conviction
2%
40-Day Fair Value
≈ by Jan 12, 2027
$83.09
α -0.2% rank 33%
conviction
7%
60-Day Fair Value
≈ by Feb 10, 2027
$83.06
α -0.2% rank 33%
conviction
5%
MethodImplied PriceWeightDetail
DCF $47.99 21%
DDM (Gordon) n/a 0%
Peer P/E $94.57 9% median 34.9× · 7 peers
Peer EV/EBITDA $84.78 9% median 20.5× · 7 peers
Peer P/B $43.70 2% median 6.6× · 8 peers
Peer P/S $117.64 6% median 8.3× · 8 peers
Market Anchor (SMA50) $84.43 31% stability 75% (BB-width)
Options Expected (B-L 30d) $80.97 21% 33 strikes · skew +0.81
As of 2026-11-13 · updated
About
Industry (SIC)
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
Exchange
XNAS
Market Cap
$30.4B
Employees
11,100
List Date
2005-04-14
CIK
0001093557
Last Earnings
Oct 29 after close · +3.0% vs ±7.9% expected
Next Earnings
~Feb 11, 2027 (estimated)
Headquarters
San Diego, CA
Homepage
https://www.dexcom.com

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: E earnings, with the move options implied and the move that happened (amber when the stock moved more than implied) · ▲ ▼ insider open-market buys and sales, sized by dollar value · S splits. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
'21'22'23'24'25'26Avg
Jan4.78%-17.34%-6.66%-1.41%10.61%9.77%-0.04%
Feb3.96%-4.86%3.06%-6.14%1.52%1.24%-0.20%
Mar-9.40%25.27%4.89%13.93%-20.58%-14.88%-0.13%
Apr5.64%-23.14%5.29%-7.65%6.03%-4.52%-3.06%
May-2.94%-26.82%-1.00%-5.65%22.12%20.20%0.98%
Jun16.77%5.03%7.47%-1.61%2.08%-10.04%3.28%
Jul20.77%5.73%-1.94%-39.54%-3.36%21.15%0.47%
Aug3.53%-1.93%-17.23%-1.39%-4.97%4.30%-2.95%
Sep0.36%-3.06%-8.44%-7.35%-9.43%-4.27%-5.36%
Oct13.33%42.13%-6.05%6.79%-11.89%-4.57%6.62%
Nov-10.31%-2.32%22.72%10.86%5.03%-1.82%*4.03%
Dec-2.08%-4.06%6.41%-1.94%4.49%--0.56%
Total47.58%-22.08%3.05%-42.04%-5.19%10.69%-1.33%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $81.61
SMA 50: $84.30
SMA 200: $75.08
Current: $83.23
EMA 12: $81.92
EMA 26: $82.62
MACD: -0.6948 | Signal: 0.1679
BEARISH
ADX (14): 13.49
RANGE
+DI: 23.95
−DI: 20.26

Momentum Oscillators

RSI (14): 51.19
NEUTRAL
Stoch %K: 35.81
Stoch %D: 31.25
Williams %R: -55.89

Volume & Volatility

BB Upper: $87.48
BB Lower: $75.74
NEUTRAL
OBV: 117,116,333
Vol SMA 20: 4,939,489
Vol ROC: -81.86%
ATR: $2.94
True Range: $1.94
HV 20: 50.0%
HV 30: 46.4%
HV 60: 36.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-14T00:00:00 – 2026-11-12T00:00:00
AI Analysis
Written before DXCM’s Oct 29 earnings report, so it doesn’t reflect the results.

Here is a comprehensive stock analysis report for DXCM based on the provided data:

Executive Summary

Overall Assessment: NEUTRAL with confidence level 6 (out of 10)

Key Drivers: Growing demand for non-invasive blood glucose monitoring devices, increasing adoption in pediatric population, and positive market sentiment.

Primary Risks: High competition in the industry, regulatory hurdles, and potential volatility in stock price due to market fluctuations.

Investment Thesis: DXCM is a leading player in the diabetes technology space, with a growing portfolio of products and a strong pipeline. The company's non-invasive blood glucose monitoring system has shown significant promise, and we expect this trend to continue. However, the industry remains highly competitive, and regulatory hurdles may impact the company's growth prospects.

Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, highlighting the growing demand for non-invasive blood glucose monitoring devices and DXCM's leading position in this space. The sentiment has been driven by articles discussing the company's pediatric expansion, its growth vision for 2030, and the increasing adoption of its products.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - NEUTRAL; Medium-term (1-3 months) - BULLISH; Long-term (3-12 months) - BULLISH

Support/Resistance Levels:

  • Upper Resistance: $92.15
  • Middle Support: $89.89
  • Lower Resistance: $87.63

Momentum Signals: RSI interpretation: Neutral (52.92), indicating a lack of significant buying or selling pressure. MACD signal: Bullish, with the MACD line above the signal line, suggesting an uptrend. Bollinger Bands position: Neutral, as the price is hovering near the middle band.

Volume Analysis: Volume SMA 20: 4071508.85; On-Balance Volume (OBV): 91953873.52; Volume Rate of Change: -34.92%. The volume indicators suggest a lack of significant buying or selling pressure.

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting the growing demand for non-invasive blood glucose monitoring devices and DXCM's leading position in this space.

Sentiment Assessment: POSITIVE (aggregate sentiment from the last 10 news articles)

Catalyst Identification: Upcoming catalysts include the company's pediatric expansion, its growth vision for 2030, and potential regulatory approvals for its products.

Market Narrative: The market narrative is overwhelmingly positive, with investors expecting continued growth and adoption of DXCM's products. The recent news headlines have reinforced this sentiment, driving up the stock price.

Risk & Volatility Assessment

Beta Interpretation: Low risk relative to the market (beta = 0.66), indicating that the stock moves less than the broader market.

Volatility Regime: Current volatility levels are low (historical volatility = 24.2% for HV20, 43.7% for HV30, and 42.2% for HV60).

Options Market Signals: IV Rank: Low (18.2%), indicating historically low volatility; Current IV: 40.8%; Expected Move: $5.58 (28 DTE), 7-DTE: $3.33.

Downside Protection: Support levels include the lower resistance level of $87.63 and the middle support level of $89.89.

Market Context & Positioning

Sector Performance: DXCM is outperforming its sector peers, with a relative strength index (RSI) reading of 62.12.

Institutional Activity: The options market suggests institutional interest, with a put/call volume ratio of 1.33 and an open interest in calls exceeding that in puts.

Correlation Analysis: DXCM is negatively correlated with the broader market (R-squared interpretation).

Relative Valuation: DXCM is trading within its expected range, with a relative valuation index (RVI) reading of 0.92.

Key Levels & Action Items

Critical Price Levels:

  • Upper Resistance: $92.15
  • Middle Support: $89.89
  • Lower Resistance: $87.63

Breakout/Breakdown Levels: No significant levels to monitor in the short-term, but keep an eye on the upper resistance level of $92.15 for potential breakout signals.

Time-Sensitive Catalysts:

  • Pediatric expansion: Monitor for regulatory approvals and product launches.
  • Growth vision for 2030: Track company guidance and updates on this initiative.

Risk Management: Stop-loss levels can be set at $85.17, with position sizing considerations based on volatility and risk tolerance.

Please note that this analysis is based on the provided data and may not reflect actual market performance or future stock price movements.

Generated
News
All DXCM news →
Showing 1–10 of 13
Page 1 of 2
Earnings History
18 of 24 under expected move
Avg Expected Move
9.98%
Avg Actual Move
8.45%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2021-01-11 After-Close 4.77% 2.82% 0.59x Within
2021-04-29 After-Close 8.99% 8.44% 0.94x Within
2021-07-29 After-Close 8.26% 13.04% 1.58x Exceeded
2021-10-28 After-Close 9.84% 9.27% 0.94x Within
2022-01-10 After-Close 7.46% 4.07% 0.55x Within
2022-04-28 After-Close 12.76% 1.13% 0.09x Within
2022-07-28 After-Close 12.13% 5.64% 0.46x Within
2022-10-27 After-Close 12.15% 19.38% 1.60x Exceeded
2023-01-09 After-Close 6.83% 0.75% 0.11x Within
2023-04-27 After-Close 10.17% 1.81% 0.18x Within
2023-07-27 After-Close 9.28% 2.33% 0.25x Within
2023-10-26 After-Close 13.94% 10.11% 0.73x Within
2024-01-08 After-Close 4.03% 0.05% 0.01x Within
2024-04-25 After-Close 6.99% 9.91% 1.42x Exceeded
2024-07-25 After-Close 11.45% 40.66% 3.55x Exceeded
2024-10-24 After-Close 17.47% 1.88% 0.11x Within
2025-02-13 After-Close 8.56% 5.92% 0.69x Within
2025-05-01 After-Close 11.03% 16.17% 1.47x Exceeded
2025-07-30 After-Close 9.88% 9.31% 0.94x Within
2025-10-30 After-Close 14.81% 14.63% 0.99x Within
2026-02-12 After-Close 10.99% 7.59% 0.69x Within
2026-04-30 After-Close 10.83% 3.02% 0.28x Within
2026-07-30 After-Close 9.02% 11.95% 1.32x Exceeded
2026-10-29 After-Close 7.88% 2.95% 0.37x Within

Earnings calendar: this week’s reports with expected vs actual moves →

DXCM Options Activity & IV Rank

DXCM IV rank history, 52-week IV rank and IV percentile →

Volatility Metrics

Current IV: 37.0%
7-DTE IV: 34.8%
Expected Move: $6.80
7-DTE Move: $3.47
Days to Exp: 28 (2026-12-11)

Options Flow · All expiries

Call Volume: 2,962
Put Volume: 3,357
P/C Volume: 1.133
NEUTRAL
Call OI: 50,233
Put OI: 45,798
P/C OI: 0.912
Total OI: 96,031

ATM Options Pricing

ATM Call: $3.75
ATM Put: $3.05
Call %: 4.5%
Put %: 3.7%

Chain Summary

Chain Volume: 6,319
Chain OI: 96,031
Last Updated: 11/13/2026
Spread Scanner
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 69th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
69%
vs own history
GEX tilt
+0.23
OI-weighted, today
Vanna tilt
+0.45
δ-sensitivity to IV
Charm tilt
-0.54
δ-decay vs time
Vanna tilt +0.45: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.54: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 80 ATM contracts, 32k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put 74%
+8.9 pts EXTREME
ATM 36.2% / Put 45.2%
30 DTE / 10d put 44%
+5.8 pts EXTREME
ATM 36.4% / Put 42.2%

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)14.5LowNov 13
IV Rank (30 DTE)25.3MediumNov 13

Embed DXCM IV rank

DXCM's 30-day IV rank (90 sessions) with its 52-week rank, at-the-money IV and a 90-session trend. Updates after each close. Paste the code into any web page or blog post. Email newsletters drop iframes, so link to the page there.

Theme
Preview
Straddle Price (30 DTE)$6.80Nov 13
Beta Analysis

Risk Metrics

Beta: 0.7029
Alpha: 31.70%
Correlation: 0.2529
R-Squared: 6.4%
Stock Volatility: 37.9%
Market Volatility: 13.6%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own DXCM
8 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Citadel Hedge fund
Ken Griffin
$165.8M
0.10%
#240 of 6285+130.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$109.8M
0.15%
#136 of 3138+3.0%13F
Soros Fund Management Family office
George Soros, Robert Soros, Jonathan Soros
$63.5M
0.83%
#38 of 251+7.9%13F
Oaktree Capital Asset manager
Howard Marks
$57.1M
1.09%
#24 of 130+51.3%13F
Millennium Management Hedge fund
Izzy Englander
$29.5M
0.02%
#890 of 3716+117.0%13F
Bridgewater Associates Hedge fund
Ray Dalio
$27.0M
0.11%
#153 of 997+187.0%13F
Point72 Hedge fund
Steve Cohen
$19.0M
0.03%
#597 of 1945+9.9%13F
Rockefeller Capital Management Family office
Rockefeller family
$1.2M
0.00%
#1610 of 4729+16.1%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

DXCM Institutional Ownership (13F)

Filings for 2026-06-30 · 526 already for 2026-09-30
Diluted shares outstanding: 391,525,000 (as of 2026-09-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

1,064 filers2,819,371,139 shares$28.51B value720.10% of float
# Filer Shares Value % of Total % of Float Period
1 BlackRock, Inc. Custodian 181,839,137 $2.71B 9.51% 46.44% 2026-06-30
2 Vanguard Capital Management LLC 25,209,752 $1.70B 5.96% 6.44% 2026-06-30
3 Vanguard Portfolio Management LLC 19,656,540 $1.32B 4.64% 5.02% 2026-06-30
4 State Street Corp 50,705,806 $1.27B 4.45% 12.95% 2026-06-30
5 Geode Capital Management, LLC Custodian 12,459,159 $1.07B 3.76% 3.18% 2026-09-30
6 Invesco Ltd. Custodian 15,288,133 $1.03B 3.61% 3.90% 2026-06-30
7 BAILLIE GIFFORD & CO 14,801,590 $996.89M 3.50% 3.78% 2026-06-30
8 Amundi Custodian 10,766,555 $978.61M 3.43% 2.75% 2026-09-30
9 UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Custodian 11,261,876 $758.49M 2.66% 2.88% 2026-06-30
10 AllianceBernstein L.P. 11,693,409 $734.35M 2.58% 2.99% 2026-06-30
11 Wellington Management Group LLP Custodian 8,527,471 $574.33M 2.01% 2.18% 2026-06-30
12 Arrowstreet Capital, Limited Partnership 6,873,273 $462.91M 1.62% 1.76% 2026-06-30
13 Norges Bank 6,868,090 $462.57M 1.62% 1.75% 2026-06-30
14 UBS Group AG Custodian 11,114,779 $413.24M 1.45% 2.84% 2026-06-30
15 Morgan Stanley Custodian 7,131,282 $349.12M 1.22% 1.82% 2026-06-30
16 Ameriprise Financial, Inc. Custodian 4,849,775 $324.71M 1.14% 1.24% 2026-06-30
17 Franklin Resources, Inc. Custodian 35,845,893 $272.30M 0.96% 9.16% 2026-06-30
18 Castle Hook Partners LP 3,870,342 $260.67M 0.91% 0.99% 2026-06-30
19 JPMorgan Chase & Co Custodian 27,765,095 $255.54M 0.90% 7.09% 2026-06-30
20 Goldman Sachs Group Inc Custodian 3,758,616 $253.14M 0.89% 0.96% 2026-06-30
21 Massachusetts Financial Services Co 3,560,621 $240.92M 0.85% 0.91% 2026-06-30
22 CIBC Bancorp USA Inc. 3,454,735 $232.97M 0.82% 0.88% 2026-06-30
23 Charles Schwab Investment Management, Inc. 3,439,164 $231.63M 0.81% 0.88% 2026-06-30
24 Northern Trust Corp Custodian 3,295,144 $221.93M 0.78% 0.84% 2026-06-30
25 Bank of America Corp Custodian 10,631,604 $220.03M 0.77% 2.72% 2026-06-30
27 filers$323.91M notional
# Filer Notional Value % of Total Period
1 HSBC Holdings plc Custodian $74.49M 23.00% 2026-06-30
2 Jane Street Group, LLC Custodian $56.06M 17.31% 2026-06-30
3 Walleye Trading LLC $35.82M 11.06% 2026-06-30
4 Susquehanna International Group, LLP Custodian $32.30M 9.97% 2026-06-30
5 Citadel Advisors LLC Custodian $25.77M 7.96% 2026-06-30
6 IMC-Chicago, LLC Custodian $19.90M 6.14% 2026-09-30
7 Royal Bank of Canada Custodian $18.86M 5.82% 2026-06-30
8 UBS Group AG Custodian $15.13M 4.67% 2026-06-30
9 Caption Management, LLC $6.74M 2.08% 2026-06-30
10 Alphadyne Asset Management LP $5.89M 1.82% 2026-06-30
11 Citigroup Inc. Custodian $5.61M 1.73% 2026-09-30
12 PEAK6 LLC $5.29M 1.63% 2026-06-30
13 Simplex Trading, LLC Custodian $4.29M 1.32% 2026-09-30
14 Goldman Sachs Group Inc Custodian $4.18M 1.29% 2026-06-30
15 TUDOR INVESTMENT CORP ET AL $2.51M 0.78% 2026-06-30
16 GROUP ONE TRADING LLC Custodian $1.93M 0.60% 2026-06-30
17 Millennium Management LLC Custodian $1.80M 0.56% 2026-06-30
18 Verition Fund Management LLC $1.66M 0.51% 2026-06-30
19 Walleye Capital LLC $1.49M 0.46% 2026-06-30
20 Twin Tree Management, LP $1.14M 0.35% 2026-06-30
21 Qube Research & Technologies Ltd $1.12M 0.35% 2026-06-30
22 Point72 Asset Management, L.P. $498.39K 0.15% 2026-06-30
23 Squarepoint Ops LLC $404.10K 0.12% 2026-06-30
24 SG Americas Securities, LLC $399.00K 0.12% 2026-06-30
25 Raymond James Financial, Inc. Custodian $300.00K 0.09% 2026-06-30
27 filers$353.85M notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $117.26M 33.14% 2026-06-30
2 Citadel Advisors LLC Custodian $78.54M 22.20% 2026-06-30
3 UBS Group AG Custodian $31.90M 9.01% 2026-06-30
4 Goldman Sachs Group Inc Custodian $19.35M 5.47% 2026-06-30
5 Citigroup Inc. Custodian $17.26M 4.88% 2026-09-30
6 Jane Street Group, LLC Custodian $16.05M 4.54% 2026-06-30
7 Walleye Trading LLC $14.53M 4.11% 2026-06-30
8 HSBC Holdings plc Custodian $11.14M 3.15% 2026-06-30
9 IMC-Chicago, LLC Custodian $10.42M 2.95% 2026-09-30
10 Simplex Trading, LLC Custodian $9.30M 2.63% 2026-09-30
11 Alphadyne Asset Management LP $5.62M 1.59% 2026-06-30
12 Millennium Management LLC Custodian $3.33M 0.94% 2026-06-30
13 D. E. Shaw & Co., Inc. Custodian $2.91M 0.82% 2026-06-30
14 Qube Research & Technologies Ltd $2.60M 0.73% 2026-06-30
15 Twin Tree Management, LP $2.56M 0.72% 2026-06-30
16 PEAK6 LLC $2.36M 0.67% 2026-06-30
17 Squarepoint Ops LLC $2.05M 0.58% 2026-06-30
18 CAPSTONE INVESTMENT ADVISORS, LLC $1.87M 0.53% 2026-06-30
19 TUDOR INVESTMENT CORP ET AL $1.35M 0.38% 2026-06-30
20 Lido Advisors, LLC $1.16M 0.33% 2026-09-30
21 Verition Fund Management LLC $814.93K 0.23% 2026-06-30
22 GROUP ONE TRADING LLC Custodian $626.36K 0.18% 2026-06-30
23 BNP Paribas Financial Markets Custodian $505.12K 0.14% 2026-06-30
24 Walleye Capital LLC $262.67K 0.07% 2026-06-30
25 Marshall Wace, LLP Custodian $53.88K 0.02% 2026-06-30

DXCM Insider Trading (Form 4)

Latest: 2026-11-10
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-11-10 Sadie Stern EVP Chief People & Culture Off Tax (F) −1,451 $79.41 -$115.2K EDGAR
2026-11-10 Jereme M Sylvain EVP, COO & CFO Tax (F) −1,451 $79.41 -$115.2K EDGAR
2026-11-10 Jacob Steven Leach President, CEO, and Director Tax (F) −1,451 $79.41 -$115.2K EDGAR
2026-11-10 Michael Jon Brown EVP Chief Legal Compliance Off Tax (F) −1,451 $79.41 -$115.2K EDGAR
2026-11-03 Euan A. Ashley Director Gift (G) −2,389 — EDGAR
2026-10-28 Sadie Stern EVP Chief People & Culture Off Sell (S) −2,565 $78.62 -$201.7K EDGAR
2026-10-19 Michael Jon Brown EVP Chief Legal Compliance Off Sell (S) −1,700 $85.48 -$145.3K EDGAR
2026-09-30 Sadie Stern EVP Chief People & Culture Off Sell (S) −2,565 $86.15 -$221.0K EDGAR
2026-09-16 Michael Jon Brown EVP Chief Legal Compliance Off Sell (S) −1,700 $84.04 -$142.9K EDGAR
2026-09-16 Nicholas Augustinos Director Sell (S) −8,089 $84.04 -$679.8K EDGAR
2026-09-14 Jereme M Sylvain EVP, Chief Financal Officer Sell (S) −3,638 $83.27 -$302.9K EDGAR
2026-09-10 Glenn S Boehnlein Director Award (A) +5,841 — EDGAR
2026-08-28 Sadie Stern EVP Chief People & Culture Off Sell (S) −2,565 $88.37 -$226.7K EDGAR
2026-08-25 Sadie Stern EVP Chief People & Culture Off Tax (F) −1,451 $92.34 -$134.0K EDGAR
2026-08-25 Jereme M Sylvain EVP, Chief Financal Officer Tax (F) −1,451 $92.34 -$134.0K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

DXCM Insider Holdings

20 insiders · @ $83.23
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Jacob Steven Leach President, CEO, and Director 464,753 $38.68M -$52.55M 47 2026-11-10
2 Eric Topol Director 380,545 $31.67M -$5.36M 22 2025-05-12
3 Kevin R Sayer Executive Chair 302,214 $25.15M -$194.08M 119 2026-08-24
4 Jereme M Sylvain EVP, COO & CFO 145,377 $12.10M -$9.00M 43 2026-11-10
5 Sadie Stern EVP Chief People & Culture Off 119,462 $9.94M -$8.33M 42 2026-11-10
6 Jon Coleman EVP, Chief Commercial Officer 100,361 $8.35M -$722.6K 4 2026-06-05
7 Michael Jon Brown EVP Chief Legal Compliance Off 96,734 $8.05M -$5.60M 32 2026-11-10
8 Steven R Altman Director 69,232 $5.76M -$17.38M 37 2026-06-01
9 Mark G Foletta Director 57,183 $4.76M -$5.96M 39 2026-08-04
10 Richard Alexander Collins Director 45,767 $3.81M -$2.50M 17 2026-06-01
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

DXCM Board & Officers

As of SEC filings through Nov 10, 2026

Directors 13

Officers 6

Changes in the last 10 years (73)
Sep 10, 2026Glenn S Boehnlein became a director
May 27, 2026Sadie Stern listed as EVP Chief People & Culture Off (previously EVP, Chief HR Officer) in SEC filings
May 27, 2026Michael Jon Brown listed as EVP Chief Legal Compliance Off (previously EVP, Chief Legal Officer) in SEC filings
Feb 26, 2026Albert Frederick Osterloh IV became a director
Feb 2, 2026Kevin R Sayer listed as Executive Chair (previously President, CEO and Chairman) in SEC filings
Feb 2, 2026Jacob Steven Leach listed as President, CEO, and Director (previously EVP, Chief Operating Officer) in SEC filings
Feb 2, 2026Jacob Steven Leach first listed as a director in an SEC filing
Oct 24, 2025Euan A. Ashley became a director
May 12, 2025Karen M Dahut reported in an SEC filing no longer being a director
May 12, 2025Eric Topol reported in an SEC filing no longer being a director
Mar 31, 2025Jon Coleman became EVP, Chief Commercial Officer
Mar 6, 2025Renee D Gala became a director
Sep 11, 2024Jereme M Sylvain listed as EVP, Chief Financal Officer (previously EVP Chief Financial Officer) in SEC filings
Jun 11, 2024Sadie Stern listed as EVP, Chief HR Officer (previously EVP Chief Human Resources) in SEC filings
Apr 16, 2024Matthew Vincent Dolan listed as EVP Strategy and Corporate Dev (previously EVP Strategy and Corporate) in SEC filings
Mar 11, 2024Matthew Vincent Dolan listed as EVP Strategy and Corporate (previously SVP Corporate Strategy-Develop) in SEC filings
Jan 17, 2024Sadie Stern listed as EVP Chief Human Resources (previously EVP Chief Human Resources Offi) in SEC filings
Jan 17, 2024Jacob Steven Leach listed as EVP, Chief Operating Officer (previously EVP Chief Technology Officer) in SEC filings
Aug 24, 2023Rimma Driscoll became a director
Mar 14, 2023Andrew K Balo reported in an SEC filing no longer being *
Not reported recently (16)
  • Matthew Vincent Dolan · Last reported as EVP Strategy and Corporate Dev in an SEC filing dated Jan 30, 2025
  • Barbara Kahn · Last reported as a director in an SEC filing dated May 21, 2024
  • Teri L Lawver · Last reported as EVP Chief Commercial Officer in an SEC filing dated Mar 14, 2024
  • Barry J. Regan · Last reported as EVP Operations in an SEC filing dated Dec 19, 2023
  • Paul R Flynn · Last reported as EVP Global Revenue in an SEC filing dated Dec 19, 2023
  • Steven Robert Pacelli · Last reported as EVP Managing Director Dexcom V in an SEC filing dated Nov 27, 2023
  • Girish Naganathan · Last reported as EVP Chief Technology Officer in an SEC filing dated Nov 27, 2023
  • Shelly Ramasamy Selvaraj · Last reported as SVP Chief Information Officer in an SEC filing dated Sep 12, 2023
  • Jay S Skyler · Last reported as a director in an SEC filing dated May 22, 2023
  • Donald Abbey · Last reported as EVP Global Business Services I in an SEC filing dated Mar 14, 2023
  • Sumi Shrishrimal · Last reported as SVP Chief Risk Officer in an SEC filing dated Mar 10, 2022
  • Patrick Michael Murphy · Last reported as EVP, Chief Legal Officer in an SEC filing dated Sep 13, 2021
  • Quentin S. Blackford · Last reported as Chief Operating Officer in an SEC filing dated Sep 10, 2021
  • Richard Doubleday · Last reported as EVP, Chief Commercial Officer in an SEC filing dated Mar 24, 2021
  • Jeffrey Moy · Last reported as EVP Operations in an SEC filing dated Sep 11, 2020
  • Heather S Ace · Last reported as SVP Human Resources in an SEC filing dated Mar 13, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

DXCM Proposed Insider Sales (Form 144)

Latest: 2026-10-27
Last 30d: 2 filings · $347K notice value  ·  Last 90d: 11 filings · $4.6M notice value · 6 unique filers · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: KEVIN R SAYER (1, $2.4M) · AUGUSTINOS NICHOLAS (2, $680K) · SADIE STERN (3, $649K) · MICHAEL BROWN (3, $444K) · JEREME SYLVAIN (1, $303K)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-10-27 SADIE STERN Officer 2,565 $201.7K 2026-10-27 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-10-15 MICHAEL BROWN Officer 1,700 $145.3K 2026-10-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-28 SADIE STERN Officer 2,565 $221.0K 2026-09-28 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-15 AUGUSTINOS NICHOLAS Director 6,539 $549.5K 2026-09-15 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-09-15 MICHAEL BROWN Officer 1,700 $142.9K 2026-09-15 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-09-14 AUGUSTINOS NICHOLAS Director 1,550 $130.2K 2026-09-14 Fidelity Brokerage Services LLC 10b5-1 EDGAR
2026-09-10 JEREME SYLVAIN Officer 3,638 $302.9K 2026-09-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-27 SADIE STERN Officer 2,565 $226.7K 2026-08-27 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-20 KEVIN R SAYER Officer, Director 26,756 $2.41M 2026-08-20 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2026-08-14 MICHAEL BROWN Officer 1,700 $156.3K 2026-08-14 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Filing Date Event Link
2026-10-29 Earnings results · Other events EDGAR
2026-09-14 Director or officer change · Regulation FD disclosure EDGAR
2026-09-10 Director or officer change · Regulation FD disclosure EDGAR
2026-07-30 Earnings results EDGAR
2026-05-28 Shareholder vote results EDGAR
2026-05-15 Regulation FD disclosure · Other events EDGAR
2026-04-30 Earnings results EDGAR
2026-03-02 Director or officer change EDGAR
2026-02-26 Director or officer change · Regulation FD disclosure EDGAR
2026-02-12 Earnings results EDGAR
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
Filing Date Accession Link
2026-02-12 0001093557-26-000027 EDGAR
2025-02-18 0001093557-25-000036 EDGAR
2024-02-08 0001093557-24-000021 EDGAR
2023-02-09 0001093557-23-000024 EDGAR
2022-02-14 0001093557-22-000014 EDGAR
2021-02-11 0001093557-21-000024 EDGAR
2020-02-13 0001093557-20-000029 EDGAR
2019-02-21 0001093557-19-000041 EDGAR
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
Filing Date Accession Link
2026-10-29 0001093557-26-000195 EDGAR
2026-07-30 0001093557-26-000143 EDGAR
2026-04-30 0001093557-26-000073 EDGAR
2025-10-30 0001093557-25-000280 EDGAR
2025-07-30 0001093557-25-000243 EDGAR
2025-05-01 0001093557-25-000113 EDGAR
2024-10-24 0001093557-24-000180 EDGAR
2024-07-25 0001093557-24-000144 EDGAR
2024-04-25 0001093557-24-000079 EDGAR
2023-10-26 0001093557-23-000220 EDGAR
ETF Holders
357 ETFs hold DXCM
25 shown · $6.64B total exposure · 0.08% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.04% $1.0B — 2026-09-30
2 VOO Vanguard S&P 500 ETF Vanguard 0.05% $854.9M — 2026-09-30
3 VO Vanguard Morningstar Mid-Cap ETF Vanguard 0.32% $697.3M — 2026-09-30
4 QQQ Invesco QQQ Trust, Series 1 Invesco 0.14% $644.2M — 2026-11-11
5 VUG Vanguard Morningstar Growth ETF Vanguard 0.11% $435.5M — 2026-09-30
6 IVV iShares Core S&P 500 ETF iShares (BlackRock) 0.05% $407.0M $879.1B 2026-11-11
7 SPY State Street® SPDR® S&P 500® ETF Trust SPDR (State Street) 0.05% $370.2M $805.7B 2026-11-11
8 VOT Vanguard Morningstar Mid-Cap Growth ETF Vanguard 0.77% $255.6M — 2026-09-30
9 XLV State Street® Health Care Select Sector SPDR® ETF SPDR (State Street) 0.44% $223.5M $50.5B 2026-11-11
10 RSP Invesco S&P 500 Equal Weight ETF Invesco 0.18% $194.6M — 2026-11-11
11 IWP iShares Russell Mid-Cap Growth ETF iShares (BlackRock) 0.92% $170.4M $18.3B 2026-11-11
12 IHI iShares U.S. Medical Devices ETF iShares (BlackRock) 3.75% $153.2M $4.0B 2026-11-11
13 QQQM Invesco NASDAQ 100 ETF Invesco 0.14% $148.3M — 2026-11-11
14 IWR iShares Russell Mid-Cap ETF iShares (BlackRock) 0.22% $129.1M $58.6B 2026-11-11
15 AVLV Avantis U.S. Large Cap Value ETF Avantis 0.49% $116.0M $23.6B 2026-11-11
16 IWF iShares Russell 1000 Growth ETF iShares (BlackRock) 0.10% $113.5M $118.9B 2026-11-11
17 VHT Vanguard Health Care ETF Vanguard 0.47% $101.7M — 2026-09-30
18 COWZ Pacer US Cash Cows 100 ETF Nport 0.49% $91.6M — 2026-07-31
19 SPYM State Street® SPDR® Portfolio S&P 500® ETF SPDR (State Street) 0.05% $85.8M $186.1B 2026-11-11
20 SCHG Schwab U.S. Large-Cap Growth ETF Nport 0.14% $85.2M — 2026-08-31
21 SPHQ Invesco S&P 500 Quality ETF Invesco 0.44% $84.5M — 2026-11-11
22 JEPQ JPMorgan Nasdaq Equity Premium Income ETF JPMorgan 0.19% $79.4M $42.5B 2026-11-12
23 QUAL iShares MSCI USA Quality Factor ETF iShares (BlackRock) 0.11% $54.6M $48.7B 2026-11-11
24 VONG Vanguard Russell 1000 Growth ETF Vanguard 0.10% $52.9M — 2026-09-30
25 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.06% $52.5M — 2026-11-11
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
32.76
TTM Diluted EPS
$2.54
TTM Revenue
$5.10B
TTM Net Income
$991.00M
TTM Op. Cash Flow
$1.41B
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q3 '262026-09-30$1.34B$275.10M$0.72$325.60M
Q2 '262026-06-30$1.31B$249.10M$0.64$269.20M
Q1 '262026-03-31$1.19B$199.50M$0.51$525.60M
Q4 '252025-12-31$1.26B$267.30M$0.67$294.00M
Q3 '252025-09-30$1.21B$283.80M$0.70$659.90M
Q2 '252025-06-30$1.16B$179.80M$0.45$303.00M
Q1 '252025-03-31$1.04B$105.40M$0.27$183.80M
Q4 '242024-12-31$1.11B$151.70M$0.38$301.40M
Q3 '242024-09-30$994.20M$134.60M$0.34$199.50M
Q2 '242024-06-30$1.00B$143.50M$0.35$279.40M
Q1 '242024-03-31$921.00M$146.40M$0.36$209.20M
Q4 '232023-12-31$1.03B$256.30M$0.61$133.60M
Q3 2026 • period ending 2026-09-30 • filed 2026-10-29
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
32.76
P/B
12.67
P/S
6.68
EV/EBITDA
23.77
EV/Sales
6.71
ROE
38.1%
ROA
15.5%
Div Yield
0.00%
FCF Yield
5.26%
Debt/Equity
0.47
Current Ratio
—
Market Cap
$33.22B
as of 2026-11-13

DXCM vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
LLY Eli Lilly & Co. $1.27T 46.9 +45.5% +33.8% 21
ABT Abbott Laboratories $185.8B 40.2 +10.0% −12.5% 21
ISRG Intuitive Surgical Inc. $152.5B 53.9 +20.5% −20.6% 12
VRTX Vertex Pharmaceuticals Inc $137.6B 34.8 +10.5% +19.5% 57
NTRA Natera, Inc. Common Stock $46.8B — +37.4% +40.3% 28
GEHC GE HealthCare Technologies Inc. Common S $37.0B 17.5 +6.9% +0.3% 21
RMD ResMed Inc. $33.6B 21.9 +9.0% −1.9% 10
DXCM DexCom, Inc. $30.4B 32.8 +13.0% +25.1% 26
PODD Insulet Corporation $10.4B 25.1 +26.5% −45.7% 17
Peer median $92.2B 34.8 +15.5% −0.8% 21

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
15.69M
SI % of Float
4.17%
Days to Cover
4.75
Short Vol Ratio
81.9%
Free Float
375.93M
Float %
99.6%
Short interest 2026-10-15 • Short volume 2026-11-12 • Float 2026-08-07